ADC Therapeutics (ADCT) Set to Announce Quarterly Earnings on Monday

ADC Therapeutics (NYSE:ADCT) will issue its quarterly earnings data before the market opens on Monday, May 6th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

ADC Therapeutics (NYSE:ADCT) last posted its quarterly earnings data on Wednesday, March 13th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.56). ADC Therapeutics had a negative net margin of 344.15% and a negative return on equity of 1,313.37%. The company had revenue of $16.79 million during the quarter, compared to analyst estimates of $16.58 million. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ADC Therapeutics Trading Up 3.6 %

NYSE ADCT opened at $4.90 on Friday. ADC Therapeutics has a 12 month low of $0.36 and a 12 month high of $6.04. The firm has a market capitalization of $405.77 million, a PE ratio of -1.68 and a beta of 1.69. The business’s 50-day moving average price is $4.59 and its two-hundred day moving average price is $2.79.

Analyst Upgrades and Downgrades

ADCT has been the subject of a number of recent analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $8.00 target price on shares of ADC Therapeutics in a research report on Thursday, March 14th. Guggenheim reaffirmed a “buy” rating on shares of ADC Therapeutics in a research report on Friday, April 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of ADC Therapeutics in a research report on Monday, April 15th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $7.50.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.